COVID-19 remained to be a hot topic among readers of MHE as it is still affecting thousands, weekly. Articles about COVID-19 that were most-read by our audience resulted with the effects of Paxlovid at the top to the the BA.5 variant.
Advertisement
Paxlovid Rebound: Rare But Real Mayo Clinic researchers reported in the journal Clinical Infectious Diseases that less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19. Read more
Pandemic Mortality Rate Much Lower in Canada Than in the US. Why? Some researchers have pointed to the benefits of a single-payer system such as the one in Canada. But the author of the PNAS commentary, David Fisman, say it may be trace back to the more communitarian outlook of Canadians. Read more
It’s Not Just COVID. There’s Also Long Flu and Pneumonia Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is an open question. Read more
Working Paper Finds COVID-19 Lockdowns Had Little Public Health Effect and Draws Criticism of Being Flawed The conclusion of the pre-print meta-analysis is that small effect of "nonpharmaceutical interventions" on COVID-19 mortality rates did not outweigh the effects of lockdowns. Read more
The BA.5 Variant Is Now Dominant: What News Outlets, Social Media Are Saying White House COVID-19 coordinator Ashish Jha tweeted that “we know how to manage this moment.” News coverage and social media posting about the BA.5 variant crested as the variant became the dominant strain circulating in the U.S. Read more
Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.